Carcinoid Tumors

Published Date : Feb 2024
Category : Oncology
Delivery Timeline : 48 hrs
Buy NowOrder by POGet a quote
Login To Access

Shedding Light on Carcinoid Tumors: Revealing Diagnosis and Treatment Approaches

Carcinoid tumors have become a major global health concern in recent years, with a large disease burden. Carcinoid tumors are considered rare neuroendocrine neoplasms, but their frequency has been rising over time, making it difficult for researchers and physicians to fully understand their intricacies. These tumors need to be thoroughly investigated to improve early identification, better treatment methods, and improve patient outcomes because of their varied clinical presentations and propensity for metastasis.

The incidence rate of the Carcinoid tumor is significantly increasing year to year. According to the National Institutes of Health (NIH) the incidence rate of carcinoid tumor is 2.5 to 5 persons per 100,000 people. The highest number of patients includes the people with the age range of 50 to 70 years. The advancements in the detection technologies of carcinoid tumor helping to detect the disease rapidly. Nearly 4000 cases are confirmed every yearly in USA. However, the incidence rate is changes as per change in the country. For instance, the incidence rate in USA is 17 cases per 100,000 in other hand in Canada it is 0.74. The carcinoid tumor is the slow growing tumor which is originated from the neuroendocrine cells and are able to secret the variety of neuroamines and peptides.

Moreover, the cancer is affecting the majorly small intestine and basically ovaries or kidneys. The prevalence of the carcinoid tumor is 35 per 100,000 persons. Survival rate of the carcinoid diseases is 85-90% in localized lesion. The increase in the prevalence of the Carcinoid tumor disease is driver for both diagnostic and treatment market of Carcinoid tumor. Carcinoid tumor disease majorly divided in two types:

  • Localized
  • Metastatic

The localized carcinoid tumor does not spread it affect the specific part or region where as the metastatic carcinoid tumor spread the or affects the other parts of body. The disease shows the various types of symptoms as follows;

  • Low red blood cell count, or anemia
  • Weakness or exhaustion.
  • Cardiac sound caused by cardiac muscle harm.
  • Yellowing of the skin
  • Hypotension, or low blood pressure
  • Vomiting as well as nausea.
  • Bleeding in the rectal area
  • A lack of breathing (dyspnea).
  • Weight loss
  • Gasping for air.

Diagnostic Analysis

The diagnostic market is majorly driven by the advancements in the diagnostic tool and new invention in the field of carcinoid tumor. According to the American Cancer Society the FDA has approved Gallium-68 PET/CT Dotatate scan which is advanced in the diagnosis of the carcinoid of the GI tract. The main diagnostic categories mentioned below are those that have a major impact on the market, depending on a number of factors including the incidence of disease and the development of diagnostic technology.

  • Imaging Test
  • Computed tomography (CT) scan
  • MRI
  • Other technologies.
  • Laboratory Testing
  • Endoscopy

Imaging Test

The imaging test for carcinoid tumor includes MRI and CT scans. Due to the availability, accessibility and accuracy of these diagnostic tools these are frequently used in the diagnosis process. A CT scan is an imaging technique which reveals the location, size, and type of carcinoid tumors using X-rays to provide detailed images of the organs.

Moreover, MRI is used in the diagnosis of carcinoid tumor basically is work by employing the magnetic and radio waves to provide sectional image of the body part. The market of diagnosis of the carcinoid is driven by the technological advancements in the diagnostic tool of the carcinoid tumor. However, the prevalence of cancerous tumors is also driving the carcinoid tumor market.

Carcinoid tumors are typically detected by a specialized scan called an OctreoScan. After the injection of a radioactive material that is taken up by carcinoid tumor cells, this scan is performed.

Laboratory Testing

Laboratory testing basically includes the blood tests and urine tests. The body of the carcinoid tumor affected patients basically contains the high level of the hormones which is released by a carcinoid tumor or byproducts those hormones found by the blood testing. Urine test detect the high level of the chemicals in the urine which is produced by body at the time of breakdown of hormones. Increase in the incidences of carcinoid tumors cases is driving the use of laboratory testing which is positively affects the market growth of carcinoid disease.


In endoscopy the camera with light is inserted in the GI track by using very tiny tube to examine the carcinoid tumor location, size, and type.

Top Players of Diagnostic Kits

The market for carcinoid tumor testing is fragmented worldwide since there are several major participants in the industry that have a global presence. The top carcinoid tumor diagnostic kit manufacturers are listed in the table below.




Product Portfolio


Siemens Healthineers



GE HealthCare



Koninklijke Philips N.

MR 7700


 Hitachi, Ltd. 



 Canon Medical Systems, USA

Vantage Galan 3T


Shimadzu Corporation

MobileDaRt Evolution MX8 Version





Aspect Imaging Ltd.

M3 compact



Aurora® 1.5T 


 Informa PLC.

i_Open 0.36T/0.4T/0.5T


Environmental XPRT

i_Magnate 1.5T 


Treatment Analysis

There are several types of treatments and therapies available in the treatment of carcinoid tumor. The treatment market of the carcinoid treatment is significantly driven by the advancements in the treatment and approval to the various drugs by the FDA. For instance The Food and Drug Administration approved selpercatinib (Retevmo, Eli Lilly and Company) on September 21, 2022, under an accelerated approval process for adult patients with solid tumors that are metastatic or locally advanced and have a RET gene fusion. The treatment of the carcinoid tumor listed below.

  • Surgery
  • Chemotherapy
  • Octreotide
  • Targeted drug therapy
  • Liver treatment


Surgery is used to remove a carcinoid tumor entirely. When carcinoid tumors are found, they are able to be completely removed. To assist manage symptoms and signs, physicians try to remove as much of the tumor as they possible.


Chemotherapy utilizes powerful chemicals to attack tumor cells. This medication is administered intravenously (IV) or orally. When advanced carcinoid tumors are not surgically removed, chemotherapy is suggested as a treatment option.


These types of the medicines are majorly used to reduce the symptoms of the carcinoid tumor. The several key players are manufacturing this drug to stay competitive in market.

Targeted drug therapy

Targeted medication therapies focus on particular defects found inside tumor cells. Targeted medication therapies kill tumor cells by inhibiting these abnormalities. Chemotherapy is typically used together with targeted drug therapy for advanced carcinoid tumors.

Liver treatment

The carcinoid tumor is usually spread to the liver. Treatment basically includes the chemotherapy drugs which are injected in the liver by the IV route which basically block the blood flow to the tumor. That result in the death of the carcinoid tumor.

Treatment Market Player

Some of major players of the treatment of the carcinoid tumor are listed below



Treatment Market Player

Treatment Product



Novartis AG



Teva Pharmaceutical Industries Ltd.

Octreotide acetate



CARBOWEL 150MG INJ(Carboplatin)


Wellona pharma

Carboplatin Injection


Xediton pharmaceutical Inc.

Vepesid® (Etoposide) Capsules


Dr Reddy




CARBOPLATIN (carboplatin)


Get well oncology



U & V Cancure Private Limited



Accord Healthcare









Regulatory Framework for Carcinoid Tumor

A DiseaseLandscape Insights significantly improves the development of the regulatory framework for carcinoid tumor and is based on the legal requirements of several countries. It offers data-driven insights for risk estimation, global collaboration, monitoring, regulation, and research direction.

The market of carcinoid tumor is driven by the various factors which include the drug approval, technological advancements and prevalence of diseases. For instance recently the FDA approved selpercatinib (brand name Retevmo) for adult patients with solid malignancies that are locally progressed or metastatic on September 21, 2022.

The approval for various drugs significantly accelerates the further research and developments in treatment of carcinoid tumor.  

Competitive Analysis

  • Top businesses in the global market have been concentrating on new product releases and enhancing their testing capabilities in order to meet the rising demand for early detection and strengthen their competitive position. They also used a variety of strategies, including as joint ventures, acquisitions, and mergers, to expand and improve the range of their products.
  • Partnerships and teamwork have also been employed by significant market players to grow their product ranges and enter new markets. For instance Arvinas and Pfizer announce the partnership on December 05, 2023 for the further discovery and development.
  • Mergers and acquisitions have also been a common strategy in the carcinoid tumor disease market, as it allows key market players to expand their market share and product portfolio. Roche is entering the obesity industry with an initial investment of $2.7 billion. Following the acquisition, Roche will be in charge of Carmot Therapeutics.

Clinical Assessment

Building up and carrying out clinical trials for new drugs and treatments, attracting patient’s strategies, regulatory compliance, ensuring successful trial outcomes, etc., is all made easier with the help of DiseaseLandscape Insights. The study titles of the ongoing clinical trials in the field of carcinoid tumor disease are shown in the table below, along with the phases in which they are now being done.

Phase 1

Phase 2

Phase 3

A Phase I Study of Safety and Immunogenicity of Survivin Long Peptide Vaccine (SurVaxM) in Patients With Metastatic Neuroendocrine Tumors (NETs)

A Randomized, Parallel Group Study to Evaluate the Safety, Pharmacokinetics, and Dose Response of Paltusotine Treatment in Subjects With Carcinoid Syndrome

Phase 1b/3 Global, Randomized, Controlled, Open-label Trial Comparing Treatment With RYZ101 to Standard of Care Therapy in Subjects With Inoperable, Advanced, SSTR+, Well-differentiated GEP-NETs That Have Progressed Following Prior 177Lu-SSA Therapy

A Phase I/IIa First-in-Human Study of [212Pb]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors

A Phase I/IIa First-in-Human Study of [212Pb]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors

TELEHEART: Telotristat Ethyl in a Heart Biomarker Study

Phase I/II Study of Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)

Personalized Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: A Phase 2 Study



Monitoring Telotristat Ethyl Inhibition of Tryptophan Hydroxylase (TPH) in Neuroendocrine Tumors Using ?-[11C]Methyl-L-tryptophan (AMT)-PET



Phase Ib/II, Open-Label Study of EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers



Phase I/II Study of Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)




DiseaseLandscape Insights (DLI) helps companies build and run effective strategies to prevent and control Carcinoid Tumors epidemics. Furthermore, as awareness and anticipated epidemics grow, there is a growing demand for diagnostic tools, clinical evaluations, and novel therapeutics.

Major players involved in the production of medicinal items benefit from the information and experience provided by DiseaseLandscape Insights. The assistance provided by DLI facilitates patient recruitment strategies, regulatory compliance, and the planning and execution of clinical trials for novel medications and pharmaceuticals.

This ultimately motivates the leaders to conduct qualitative research, investigate manufacturing companies, and find out about raw material sources. All industry participants gain a stronger position in Carcinoid Tumors disease and keep one step ahead with the help of DiseaseLandscape Insights.

Vishal SawantBusiness Development

How we can help?

  • 1-888-853-7040 - U.S. (TOLL FREE)
  • +44-1173181773 - U.K. OFFICE
  • +91-7447409162 - INDIA OFFICE
1Chat With UsBook AppointmentBook 15 min Free Analyst Call
We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us
  • FAQ
Disease Landscape Insights LLP
6th Floor, Sr No.207, Office A H 6070 Phase 1, Solitaire Business Hub, Viman Nagar, Pune, Maharashtra, 411014
1-888-853-7040 - U.S. (TOLL FREE)+44-1173181773 - U.K. OFFICE+91-7447409162 - INDIA OFFICE
© Copyright 2024-25 Disease Landscape Insights LLP. All Rights Reserved | Designed by Disease Landscape